Cell and gene therapy candidates have been demonstrated to have the potential to treat complex and rare diseases, including indications, for which no effective treatment is currently available. In this context, it is important to mention that, in case of cell therapy, human cells are transplanted to repair or replace the damaged cells / tissues, thereby, enabling their treatment through alteration or restoration of certain sets of cells. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells). On the other hand, gene therapy aims to correct the underlying genetic problem to ensure the treatment, as well as prevention of diseases, by replacing, inactivating or introducing genes into cells, either inside or outside of the body. It is worth highlighting that some therapeutic interventions can be considered both cell and gene therapies. The mechanism of action of such therapies usually involves alteration of genes in specific types of cells and then, their insertion into the patient body.
How is the research and development (R&D) activity evolving in the cell and gene therapy industry?
At present, cell and gene therapy industry is one of the fastest growing therapeutic segments, already having contributed to some of the most significant disruptions in the biopharmaceutical domain. Till date, 23 cell and gene therapies have been approved by the Food and Drug Administration (FDA) in the US, while more than 1,000 IND applications have been filed for candidates being evaluated in ongoing clinical studies. This further indicates a remarkable scientific progress and therapeutic promise of these breakthrough drug candidates.
What is the need for contract research organizations (CROs) in the cell and gene therapy domain?
At present, only a few therapeutic developers have the required technical expertise to carry out in-house clinical research. This can be attributed to the high costs associated with acquiring the necessary infrastructure and capabilities to carry out research. Other key concerns shared by contemporary innovators include limited availability of expertise, high rate of attrition of pipeline drugs / therapies and prolonged development timelines. The aforementioned challenges are believed to be the key factors for driving the outsourcing of research operations to a cell and gene therapy CRO, which claim to be well-aware of the nuances of advanced therapy medicinal products (ATMPs) design and development, as well as cell and gene therapy manufacturing process.
What are the current opportunities in the cell and gene therapy CRO market?
Due to the upsurge in the research and development related to genetic engineering, there has been a considerable increase in the development of cell and gene therapies. Consequently, there has been a parallel rise in outsourcing of services as more clinical studies are anticipated to start. Specifically, cell and gene therapy companies have made significant investments to support the development / adoption of advanced tools, technologies and platforms, to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. Further, CROs are believed to play a significant role in the successful approval of these drugs in a highly evolving regulatory environment. Since 2005, over 40 CROs have been established in this domain. It is worth mentioning that cell and gene therapy CROs are bolstering their existing capabilities to offer a wide range of services to their clients.
What are the recent developments and expected trends in the cell and gene therapy industry?
Presently, more than 3,570 cell and gene therapies are being evaluated across various stages of clinical development for a myriad of disease indications. Given that the demand for cell and gene therapies is indubitably rising, more than 53% mergers and acquisitions have been undertaken by service providers in this market, since 2015. Considering the prevalent trends and projected opportunity associated with the overall cell and gene therapies market, we believe that the cell and gene therapy CRO market is likely to witness a consistent growth, till 2035.
What are the key challenges faced by cell and gene therapy CROs?
One of the key challenges faced by cell and gene therapy CROs is the lack of understanding of the standard operating procedures (SOPs). In addition, various regulatory guidelines render therapies subject to rigorous quality assessments, thereby, making it difficult for firms with limited finances to undertake research initiatives.
What are the key value drivers in the cell and gene therapy market?
A significant rise in healthcare expenditure, R&D spending and booming research have emerged as key value drivers in the cell and gene therapy domain.
How is the revenue generation potential associated with cell and gene therapy CROs likely to evolve in the coming years?
The cell and gene therapy CROs market is likely to witness a substantial growth in the coming years. It is worth mentioning that, presently in terms of area of expertise, the market is likely to be driven by cell therapies, and this trend is unlikely to change in the foreseen future as well. Further, based on scale of operation, majority of the revenue share is likely to be associated with clinical operations. Specifically, in terms of global regions, the cell and gene therapy market in Asia-Pacific is likely to grow at a relatively faster pace (21%), in the long term.
Who are the key players engaged in the cell and gene therapy CROs market?
The key players engaged in this domain (which have also been capture in this report) include Altasciences, Allucent, Accelera Charles River Laboratories, Creative Biolabs, CMIC, Evotec, ICON, IQVIA, Labcorp, Medpace, PPD, Precision For Medicine, QPS and Syneos Health.
Scope of the Report
The “Cell and Gene Therapy CROs Market (3rd Edition), 2022-2035: Distribution by Area of Expertise (Cell Therapy and Gene Therapy), Scale of Operation (Clinical, Preclinical and Discovery), Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa)” report features an extensive study of the current market landscape and future potential of the cell and gene therapy CROs market, over the next decade.
The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:
- A detailed overview of the overall market landscape of the cell and gene therapy CROs, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, area of expertise (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (discovery, preclinical, clinical and commercial) and types of services offered, including [A] preclinical services (bioanalytical services, in-vivo studies, pharmacokinetic and ADME services, preclinical safety studies, toxicology studies and other preclinical services), [B] clinical services (clinical research monitoring, clinical trial management/ clinical project management, data management, safety and pharmacovigilance, and other clinical services), [C] regulatory services (GAP analysis, IND preparation, legal representation and technical dossier submission) and [D] general support services (biostatistics, consulting, post-market assessment, re-imbursement and training).
- A detailed analysis on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive developers towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.
- Elaborate profiles of key industry players (very large and large companies) based in North America, Europe and Asia-Pacific that offer contract research services for both cell and gene therapies across both preclinical and clinical scales of operation. Each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.
- A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.
- An analysis of the recent collaborations within the cell and gene therapy contract research industry, based on several relevant parameters, such as year of partnership, type of partnership, area of expertise, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022, based on several parameters, such as year, type of agreement, area of expertise, geographical location of the companies and key value drivers.
- A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
- A list of over 310 cell therapy developers that are anticipated to partner with cell therapy CROs. These players have been shortlisted based on several relevant parameters, such as developer strength (based on company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
- An in-depth analysis of nearly 235 gene therapy developers that are anticipated to partner with gene therapy CROs and have been shortlisted on the basis of several relevant parameters, such as developer strength (based on company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
- An in-depth analysis of completed, ongoing, and planned clinical studies of various cell and gene therapies, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), therapeutic area and key geographical regions.
- A detailed analysis of the total cost of ownership for large / very large cell and gene therapy contract research organizations. It features an informed estimate of direct and indirect expenses taking into consideration various relevant parameters, over a span of 20 years.
- A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.
One of the key objectives of this report was to evaluate the current opportunity and the future growth potential of the cell and gene therapy CROs market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important parameters, such as [A] area of expertise (cell therapy and gene therapy), [B] scale of operation (clinical, preclinical and discovery), [C] therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, infectious diseases, metabolic disorders, autoimmune disorders, blood disorders, rare / genetic disorders, ophthalmological disorders, and other disorders), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
Companies Mentioned
- 3P Biopharmaceuticals
- 4Clinics
- 4D Molecular Therapeutics
- AAVantgarde Bio
- AavantiBio
- aaVective
- AaviGen
- AAVogen
- Abeona Therapeutics
- Absorption Systems Systems (Acquired by Pharmaron)
- Accelera
- AccelLAB
- Accelovance
- Accord Research
- Acer Therapeutics
- Activartis Biotech
- Adaptimmune Therapeutics
- Adicet Bio
- Adrenas Therapeutics
- Aduro Biotech
- Advanced BioScience Laboratories
- Advanced Cell Diagnostics
- Advaxis
- Advent Bioservices
- Adverum Biotechnologies
- Aevitas Therapeutics
- Affinia Therapeutics
- Agathos Biologics
- AGC Biologics
- AgenTus Therapeutics
- AGINKO Research
- AGTC
- Akouos
- Akron Biotech
- Alia Therapeutics
- Allele Biotechnology and Pharmaceuticals
- Allergan (Acquired by AbbVie)
- Allife Medical Science and Technology
- Allogene Therapeutics
- Allucent (Formerly known as CATO SMS)
- Alpha Cognition
- AlphaVax
- Altasciences
- Altheia Science
- Altor BioScience
- Amarna Therapeutics
- Ambulero
- American Gene Technologies
- Amgen
- Amphera
- Amulet Capital Partners
- Anaeropharma Science
- AnGes
- Anhui Kedgene Biotechnology
- ANI Pharmaceuticals
- Anjarium Biosciences
- Ankarys Therapeutics
- HebeCell
- Anlong Biopharmaceutical
- apceth Biopharma
- Apellis Pharmaceuticals
- Applied StemCell
- ARBELE
- Argos Therapeutics
- Aruvant Sciences
- ASC Therapeutics
- Ascendance Biotechnology
- Ascidian Therapeutics
- Asklepios BioPharmaceutical
- Aspa Therapeutics
- Aspire Health Science
- Astellas Pharma
- Asterand Bioscience
- Asterias Biotherapeutics
- AstraZeneca
- Atamyo Therapeutics
- Atara Biotherapeutics
- Athersys
- Atreca
- Atsena Therapeutics
- Aurigon
- Aurora Biopharma
- Austrianova
- Autolus
- Avance Biosciences
- Avance Clinical
- Avania
- AVAX Technologies
- AviadoBio
- Avrion Therapeutics
- AVROBIO
- Axovia Therapeutics
- Basic Pharma
- Baxalta
- Baxter
- Bayer
- Be The Match BioTherapies
- Beam Therapeutics
- Beijing Biohealthcare Biotechnology
- Beijing Doing Biomedical
- Beijing Immunochina Medical Science & Technology
- Beijing Sanwater Biological Technology
- Beijing Tricision Biotherapeutics
- Beike Biotechnology
- Belief BioMed
- Bellicum Pharmaceuticals
- Bio Elpida
- BioAccess
- BioAgilytix
- BioAtla
- BioCardia
- BioCentriq
- Biogen
- Bioheng
- Bioinova
- Biointaxis
- BioIVT
- BioMarin Pharmaceutical
- Biomere
- BioNTech
- BioRestorative Therapies
- Bio-Techne
- Biotect Services
- BioVec Pharma
- Bioville
- bluebird bio
- Bone Therapeutics
- Borea Therapeutics
- BrainStorm Cell Therapeutics
- BridgeBio
- Bristol-Myers Squibb
- C3i (Center of Excellence for Cellular Therapy)
- Caladrius Biosciences
- Cambridge Biomedical
- Cambridge Gene Therapy
- Candel Therapeutics
- Capricor Therapeutics
- Capsida Biotherapeutics
- Captain T Cell
- CardioCell
- Carina Biotech
- CARsgen Therapeutics
- Car-T Shanghai Biotech
- Cartherics
- Castle Creek Biosciences
- Catalent Biologics
- Catalyst Biosciences
- Ce3
- Celgene
- Celixir
- Cell and Gene Therapy Catapult
- Cell Biotech
- Cell Genesys
- Cell Therapies
- Cell-Easy
- Cellectar Biosciences
- Cellectis
- Cellero (Acquired by Charles River Laboratories)
- Cellex Cell Professionals
- CellGenTech
- Cellin Technologies
- Cellmed
- CellMP (subsidiary of Emmecell)
- CellPraxis
- CellProtect Biotechnology
- CellProtect Nordic Pharmaceuticals
- CellProthera
- CellTrans
- Cellular Therapeutics
- Celonic
- Celsion
- Celularity
- Celyad
- CG Oncology
- CHA Biolab
- Charles River Laboratories
- Chengdu MedGenCell
- Chiltern
- Chimeric Therapeutics
- China Regenerative Medicine International
- CiMaas
- Citoxlab
- City of Hope
- Clean Cells
- Clearside Biomedical
- Clinical Network Services (CNS)
- Clinscience
- Cmed Clinical Services
- CMIC
- CO.DON
- Coave Therapeutics
- CODA Biotherapeutics
- Code Biotherapeutics
- Cogent Biosciences
- Cognate BioServices
- CoImmune
- CombiGene
- Comparative Biosciences
- Cook MyoSite
- Copernicus Therapeutics
- Corestem
- Covance
- CRC Oncology
- Creative Biolabs
- CRISPR Therapeutics
- Crown Bioscience
- CSL Behring
- CTI Clinical Trial and Consulting Services
- Cynvec
- Cytopeutics
- Cytovac
- Daiichi Sankyo
- DanDrit Biotech
- DCPrime
- Decibel Therapeutics
- Deep Science Ventures
- Delta-Vir
- Dendreon
- Diamond Pharma Services (acquired by ProPharma)
- DiNAQOR
- DiscGenics
- DNAlite Therapeutics
- DNAtrix
- Editas Medicine
- ElevateBio
- Eli Lilly
- Emendo Biotherapeutics
- Emmes
- Encoded Therapeutics
- Endocyte
- Endsulin
- enGene
- Enochian BioSciences
- Envigo
- Epeius Biotechnologies
- Ergomed
- Eureka Therapeutics
- Eutilex
- Ever Union Biotechnology
- Evotec
- Evox Therapeutics
- Excelya
- Excision BioTherapeutics
- Exegenesis Bio
- Experior
- Expression Therapeutics
- EXUMA Biotech
- Eyevensys
- Fast-Track Drugs and Biologics
- Fate Therapeutics
- FerGene (Ferring Pharmaceuticals subsidiary)
- Ferrer Internacional
- FGK Clinical Research
- Fibrocell Technologies
- Five Prime Therapeutics
- Flash Therapeutics
- Flexion Therapeutics
- Forge Biologics
- Formula Pharmaceuticals
- Fortress Biotech
- Fosun Kite Biotechnology
- Freeline Therapeutics
- Froceth
- Frontage Laboratories
- Gadeta
- Gamida Cell
- GC Cell (Previously known as Green Cross Cell)
- Geistek Pharmaceuticals
- GenCure (A subsidiary of BioBridge Global)
- Gene Therapy Research Institution
- GeneCure Biotechnologies
- Genelux
- GeneMedicine
- Genenta Science
- Genentech
- GeneOne Life Science
- GeneQuine Biotherapeutics
- Generation Bio
- Genesis Biotechnology
- Genespire
- Genethon
- GeneWerk
- Genexine
- Genflow Biosciences
- GenIbet Biopharmaceuticals
- GenoSafe
- Genprex
- GenSight Biologics
- Genzyme
- GigaGen
- GlaxoSmithKline
- Global Cell Med
- Global Center for Medical Innovation
- Glycostem Therapeutics
- Gradalis
- Graphite Bio
- Green Cross
- Green Cross LabCell
- GRI Bio
- Gsap
- Guangzhou Trinomab Biotech
- Gyroscope Therapeutics
- Heat Biologics
- Hebei Senlang Biotechnology
- Helixmith
- HemaCare
- HemoGenix
- Hemostemix
- HengRui YuanZheng Bio-Technology
- Herantis Pharma
- Histocell
- Histogenics
- Holostem Terapie Avanzate
- Homology Medicines
- Huida (Shanghai) Biotechnology
- Human Stem Cells Institute PJSC
- HuMurine Technologies
- Hunan Zhaotai Yongren Biotech
- iCarTAB BioMed
- iCell Gene Therapeutics
- ICON
- ICRC-Weyer
- iECURE
- Ikarovec
- Ilya Pharma
- Imanis Life Sciences
- Immatics
- Immune Therapeutics
- Immunicum
- ImmunoCellular Therapeutics
- Immunocore
- Immunovative Therapies
- Immutep
- IMS Health
- INC Research
- IncoCell Tianjin (A subsidiary of Boyalife)
- Incysus
- Innovative Cellular Therapeutics
- Inovio Pharmaceuticals
- inRegen
- Intas Pharmaceuticals
- Intellia Therapeutics
- International Stem Cell Corporation
- Intertek Pharmaceutical Services
- inVentiv Health
- Iovance Biotherapeutics
- IPM Biotech
- IQVIA
- ISTO Technologies
- IVERIC bio
- Ivy Life Sciences
- Jaguar Gene Therapy
- Janssen
- Janssen Pharmaceuticals
- Japan Tissue Engineering
- Jeune (A subsidiary of Krystal Biotech)
- Juno Therapeutics
- JW Biotechnology
- JW CreaGene
- Kadimastem
- Kate Therapeutics
- KBI Biopharma
- KCR
- Kuopio Center for Gene and Cell Therapy
- Kiadis Pharma
- Kiromic
- Kite Pharma
- Klinar CRO
- Kodikaz Therapeutic Solutions
- Kolon TissueGene
- Kriya Therapeutics
- Krystal Biotech
- Kubota Vision
- Kuur Therapeutics
- LabCorp
- Lacerta Therapeutics
- LatinaBA
- Legend Biotech
- Lentistem® Biotech
- Leucid Bio
- LEXEO Therapeutics
- Lifecells
- Lineage Cell Therapeutics
- Linical
- Linical Accelovance
- Lion TCR
- Living Pharma
- LogicBio Therapeutics
- Lokon Pharma
- Longeveron
- Longmore 60 Biotech
- Lovelace Biomedical
- Lumos Pharma
- Lyell Immunopharma
- Lykan Bioscience
- Lysogene
- Magenta Therapeutics
- Marino Biotechnology
- MaxCyte
- Medelis
- Medeor Therapeutics
- Medidee
- Medigene
- MEDINET
- Mediphage Bioceuticals
- MEDIPOST
- Medpace
- MedVax Technologies
- MeiraGTx
- Merck Serono
- Mesoblast
- Metagenomi
- MetbAxis
- MI Bioresearch
- Milo Biotechnology
- Minaris Regenerative Medicine
- Minovia Therapeutics
- MolecuVax
- Momotaro-Gene
- Momotaro-Gene
- Moraga Biotechnology
- MPI Research
- Multimmune
- MultiVir
- Mustang Bio
- Myosana Therapeutics
- KAEDI Biotech
- Nanoscope Therapeutics
- NantKwest
- Navega Therapeutics
- Neopharm
- NetValue BioConsulting
- NeuExcell Therapeutics
- Neuracle Genetics
- Neuralstem
- Neurocore
- Neurogene
- Neurophth Therapeutics
- Nikon CeLL innovation
- Ninevah Therapeutics
- Nkarta
- Noble Life Sciences
- Noga Therapeutics
- Nohla Therapeutics
- Noile-Immune Biotech
- Northern Therapeutics
- Northwest Biotherapeutics
- Novadip Biosciences
- Novartis
- NovaRx
- NovaTrials
- Novella Clinical
- Novex Innovations
- Novotech
- Nuntius Therapeutics
- Nuo Therapeutics
- Nuventra (Acquired by Allucent)
- OBiO Technology
- OhioHealth
- OiDE BetaRevive
- Oisin Biotechnologies
- Ology Bioservices
- OncoBay Clinical
- Oncobiomed
- Oncolys BioPharma
- Oncorus
- OncoSenX
- Opexa Therapeutics
- Opus Genetics
- ORCA Therapeutics
- Orchard Therapeutics
- Osiris Therapeutics
- Oxford BioMedica
- Oxular
- PathoQuest
- Pattern BioSciences
- PDC*line Pharma
- PeriphaGen
- PersonGen BioTherapeutics
- Pfizer
- PharmaBio
- Pharmahungary
- PharmaLex
- Pharmaron
- Pharmaseed
- Pharmicell
- Phoenix Nest
- PhorMed
- Pilgrim Quality Solutions
- Pinze Lifetechnology
- Pique Therapeutics
- Pluristem Therapeutics
- Plus Therapeutics
- Poseida Therapeutics
- PPD
- PRC Clinical
- Precigen
- Precision BioSciences
- Precision for Medicine
- Pregene ShenZhen Biotechnology
- Primera Analytical Solutions
- Promethera Biosciences
- ProPharma
- ProtaGene (Formerly known as Protagen Protein Services)
- Provia Laboratories
- PSI CRO
- PsiOxus Therapeutics
- PSNResearch
- PTC Therapeutics
- Purespring Therapeutics
- QbD
- QPS
- Q-Trials
- Quality Assistance
- Radyus Research
- Redbiotec
- Redpin Therapeutics
- Reflection Biotechnologies
- Regeneris Medical
- Regeneron
- Regeneus
- regenold
- REGENXBIO
- Rejuvenate Bio
- Remedium Bio
- ReNeuron
- Renova Therapeutics
- Research Dynamics
- Rexgenero
- Reyon Pharmaceutical
- RHEACELL
- Ring Therapeutics
- Riyadh Pharma
- Rocket Pharmaceuticals
- Roslin Cell Therapies
- Rubius Therapeutics
- S.Biomedics
- Strategic Preclinical Product Development (S2PD)
- SalioGen Therapeutics
- Sana Biotechnology
- Sangamo Therapeutics
- Sanofi
- Sarah Cannon Development Innovations
- Sarepta Therapeutics
- Saronic Biotechnology
- SBH Sciences
- Scancell
- Scandinavian CRO
- SCiAN Services
- Sclnow Biotechnology
- SCM Lifescience
- Scope International
- Seattle Genetics
- Selecta Biosciences
- Seneca Therapeutics
- Sensorion
- Sentien Biotechnologies
- Sermes CRO
- Sernova
- Servier
- Seven and Eight Biopharmaceuticals
- Shanghai BDgene Technology
- Shanghai Bioray Laboratory
- Shanghai GeneChem
- Shanghai Houchao Biotechnology
- Shanghai iCELL Biotechnology
- Shanghai Longyao Biotechnology
- Shanghai Sunway Biotech
- Shanghai Unicar-Therapy Bio-medicine Technology
- Shenzhen BinDeBio
- Shenzhen Hornetcorn Biotechnology
- Shionogi
- Sibiono GeneTech
- SillaJen
- Sinclair Research
- Sinobioway Cell Therapy
- SMS-oncology
- SMT Bio
- SNBL USA
- Solid Biosciences
- Sorrento Therapeutics
- SOTIO
- SparingVision
- Spark Therapeutics
- Spirovant Sciences
- SpliceBio
- SQZ Biotechnologies
- Stem Cell Arabia
- Stemmatters
- StrideBio
- STRM.BIO
- Sumitomo Dainippon Pharma
- Super-T Cell Cancer Company
- Surface Oncology
- Svar Life Science
- SwanBio Therapeutics
- Symbion Research International
- Syneos Health
- Synteract (Acquired by Syneos Health)
- Taconic Biosciences
- Tactiva Therapeutics
- Taiwan Bio Therapeutics
- Takara Bio
- Takeda Pharmaceutical
- Tamid Bio
- TapImmune
- Targazyme
- Targovax
- TC BioPharm
- TCR2 Therapeutics
- TCTC Group
- TeamedOn International
- TechnoPharmaSphere
- Tella
- Tenaya Therapeutics
- Tessa Therapeutics
- Tetraneuron
- TFS
- The Cell Factory (A subsidiary of Esperite)
- The Discovery Labs Center for Breakthrough Medicines
- TheraBiologics
- Theradex Oncology
- Theravectys
- ThermoGenesis
- Tianhe Stem Cell Biotechnologies
- TiGenix
- TILT Biotherapeutics
- Tmunity Therapeutics
- TNK Therapeutics
- ToolGen
- TotipotentRX
- TRACT Therapeutics
- TransCell Science
- TransCure BioServices
- Transgene
- Translational Drug Development
- TreeFrog Therapeutics
- TFS HealthScience
- Trialbee
- Triumvira Immunologics
- TVAX Biomedical
- Tyris Therapeutics
- U.S. Stem Cell
- UCB
- Ultragenyx Pharmaceutical
- uniQure Biopharma
- Universal Cells
- Urovant Sciences
- Vaccinogen
- VBL Therapeutics
- VCN Biosciences
- VectorY Therapeutics
- Vericel
- Veristat
- VetStem Biopharma
- ViGeneron
- ViroMed
- Viscofan BioEngineering
- Vivotecnia
- Voyager Therapeutics
- VREX Therapeutics
- Waisman Biomanufacturing
- Wake Forest Innovations
- WCCT Global
- WCG IRB (Formerly known as WIRB)
- West Biotherapy
- Wissenschaftlicher Service Pharma (WiSP)
- Wize Pharma
- Worldwide Clinical Trials
- Wuhan Binhui Biotechnology
- Wuhan Sian Medical Technology
- WuXi AppTec
- Wyvern Pharmaceuticals
- Xalud Therapeutics
- Xcell Biosciences
- Xcelthera
- XEME Biopharma
- XyloCor Therapeutics
- Zelluna Immunotherapy
- Zimmer Biomet
- Ziopharm Oncology
Methodology
LOADING...